

<https://doi.org/10.1038/s44259-025-00082-7>

Heteroresistance in *Enterobacter cloacae* complex caused by variation in transient gene amplification events

Check for updates

Johannes Kupke¹, Julian Brombach¹, Yuwen Fang¹, Silver A. Wolf², Lakshmi Priya Thrukonda², Fereshteh Ghazisaeedi¹, Benno Kuropka³, Dennis Hanke¹, Torsten Semmler², Niclas Nordholt⁴, Frank Schreiber⁴, Karsten Tedin¹, Antina Lübke-Becker^{1,5}, Ulrich K. Steiner⁶ & Marcus Fulde^{1,5} ✉

Heteroresistance (HR) in bacteria describes a subpopulational phenomenon of antibiotic resistant cells of a generally susceptible population. Here, we investigated the molecular mechanisms and phenotypic characteristics underlying HR to ceftazidime (CAZ) in a clinical *Enterobacter cloacae* complex strain (ECC). We identified a plasmid-borne gene duplication-amplification (GDA) event of a region harbouring an *ampC* gene encoding a β -lactamase *bla*_{DHA-1} as the key determinant of HR. Individual colonies exhibited variations in the copy number of the genes resulting in resistance level variation which correlated with growth onset (lag times) and growth rates in the presence of CAZ. GDA copy number heterogeneity occurred within single resistant colonies, demonstrating heterogeneity of GDA on the single-cell level. The interdependence between GDA, lag time and antibiotic treatment and the strong plasticity underlying HR underlines the high risk for misdetection of antimicrobial HR and subsequent treatment failure.

Antimicrobial resistance (AMR) poses severe threats to human, animal, and environmental health¹. In 2019, antibiotic resistant bacteria were associated with the deaths of 5 million people². More frightening, it has been estimated that within the next 30 years this number will increase up to 10 million annual deaths, which would surpass the number of deaths due to prevailing non-communicable diseases, such as cancer and diabetes, respectively^{2,3}. In addition to the health consequences, the AMR crisis also poses considerable economic problems for the world. The World Bank estimates that the healthcare costs caused by AMR could exceed 1 trillion US dollars by 2030⁴. It is not without reason that AMR is seen as one of the greatest medical threats to humanity this century.

A major reason for the antibiotic crisis has been the misuse and overuse of antibiotics^{5,6}. In order to reduce antimicrobial use as much as feasible, it is essential to reliably and efficiently detect bacterial pathogens and their repertoire of AMR determinants. With no end in sight to the antibiotic crisis and stagnant development of new antibiotics⁷ it is important to understand antibiotic resistance, including resistance phenomena mediated by bacterial subpopulations⁸.

Classical antibiotic resistance is based on a specific resistance factor that leads to stable, heritable resistance. Here, mutations or horizontal transfer of resistance genes, represented in the whole population, confer resistance⁹. However, antibiotic resistance can also be conferred by subpopulations that express different phenotypic traits¹⁰. One strategy of subpopulations is the formation of persister cells. Bacterial persister cells endure periods of antibiotic treatment by entering a low- or non-growing metabolic state. After withdrawal of the antibiotic, bacteria resume growth but remain susceptible to antibiotic treatments¹¹. Another phenomenon is the property of HR, whereby subpopulations of bacteria are able to grow in the presence of an antibiotic while the majority of the susceptible cell population is killed. Importantly, the heteroresistant phenotype can rapidly become a fully resistant population over time under antibiotic selection, leading to treatment failure⁸.

HR was first observed in 1947¹² and occurs in both Gram-positive and Gram-negative bacteria in response to a broad spectrum of antibiotics¹³. In addition to emerging from a subpopulation, this phenomenon is complex due to the varying antibiotic resistance levels of resistant subpopulations and their ability to revert back to susceptibility. Finally, HR can arise from

¹Department of Veterinary Medicine, Institute of Microbiology and Epizootics, Centre for Infection Medicine, Freie Universität Berlin, Berlin, Germany. ²Robert Koch Institute (RKI), MF1-Genome Competence Centre, Berlin, Germany. ³Institute of Chemistry and Biochemistry, Department of Biology, Chemistry, and Pharmacy, Freie Universität Berlin, Berlin, Germany. ⁴Federal Institute for Materials Research and Testing (BAM), Department of Materials and the Environment, Division of Biodeterioration and Reference Organisms (4.1), Berlin, Germany. ⁵Veterinary Centre for Resistance Research (TZR), Freie Universität Berlin, Berlin, Germany. ⁶Institute of Biology, Evolutionary Demography, Freie Universität Berlin, Berlin, Germany. ✉e-mail: marcus.fulde@fu-berlin.de

monoclonal populations, in which heterogeneity arises from genetically identical cells or polyclonal, where a subpopulation of cells harbouring resistance determinants is selected upon antibiotic treatment¹⁴. Thus, HR poses a challenge to conventional phenotypic AMR testing, where bacteria are generally classified as either resistant or susceptible with respect to the whole population¹⁵. Phenomena on a subpopulation level are not sufficiently detected by standard, culture-dependent techniques and may require single cell approaches¹⁶. As a consequence, HR is frequently undetected, leading to misinterpretations regarding the determination of the minimum inhibitory concentration (MIC) used in standard laboratories¹⁷. HR results in treatment failure, recurrent infections and increased mortality rates of infected individuals¹⁸.

To reliably detect heteroresistant bacteria, a better understanding of the molecular mechanisms leading to the low-level and transient forms of resistance is required. Of particular interest are bacteria of hospital acquired infections that often show resistance to last resort antibiotics. Among these so-called ESKAPE bacteria is *Enterobacter* spp, with HR to colistin, carbapenems and tigecycline^{15,19–21}. HR to colistin has been studied in *Enterobacter* spp. and found to be mediated by the PhoPQ two component system, *ecr* and an inner membrane protein, Deda^{22–24}.

HR can be stable or unstable¹⁴. Unstable gene duplication-amplifications (GDA) have been frequently reported in HR²⁵. GDA has previously been shown to confer protection against different stressors such as heat²⁶, starvation²⁷, heavy metals and pesticides²⁸. In bacterial subpopulations, GDA can also lead to antibiotic resistance *via* gene copy number effects for genes encoding antibiotic degrading enzymes²⁹, efflux pumps³⁰ or other resistance conferring genes, e.g. two component regulatory systems³¹. GDA modulate gene expression by simple copy number accumulation of genes³², but also increase the probability of acquiring genetically fixed, point mutations that can provide stable, long term resistance^{33,34}. Despite the fact that GDA is known to contribute to bacterial survival under multiple conditions, the underlying mechanisms of GDA and its associated population dynamics in HR remain elusive.

Here, we investigate a veterinary, clinical *Enterobacter cloacae* complex (ECC) strain that was isolated from a horse. The strain exhibits monoclonal HR to the third-generation cephalosporin ceftazidime (CAZ) mediated by GDA of an AmpC β -lactamase encoded by a plasmid-borne copy of *bla*_{DHA-1}. We show that GDA of a 17 kilo base pair (kbp) region located on a plasmid is causative for HR against CAZ. Cell-to-cell variations in GDA copy number underpin genomic plasticity that directly translates into phenotypic variation in antibiotic resistance and growth. Furthermore, GDA confers a fitness advantage in the presence of CAZ by shortening the lag-time and increasing growth rates. In the absence of antibiotic selection, the heteroresistant subpopulations harbouring GDAs are outcompeted. We reveal a complex interdependence between fitness, stressor (antibiotic) and GDAs, contributing to the volatile behaviour of resistant subpopulations. Our findings contribute to a better comprehension of the impact of resistant subpopulations on the detection of HR and thus on treatment failure.

Results

Identification and characterisation of the heteroresistant *Enterobacter cloacae* complex (ECC) isolate IMT 49658

During routine diagnostic, we identified a clinical ECC isolate that showed plenty of individual colonies within and distinct from the inhibition zone in an agar-disk diffusion assay with the third-generation cephalosporine CAZ as the antibiotic to be tested. We subsequently purified and re-tested these colonies against CAZ and observed an entirely resistant phenotype (Fig. 1A). The occurrence of resistant individual colonies is a characteristic of HR and provides initial indications of heterogeneity in the overall bacterial population. However, since the detection of HR in agar-disk diffusion assays often yields false-positives^{25,35}, we additionally performed time-kill and population analysis profile (PAP) assays¹³. PAP assays confirmed the heteroresistant phenotype of ECC IMT 49658 during CAZ exposure (Fig. 1B) with a subpopulation-size >0.0001% on 2 and 4 times the breakpoint concentration (The clinical breakpoint indicates the antibiotic concentration at

which the infection is considered as resistant)^{14,36}. In a time-kill assay, the ECC isolate similarly showed a growth pattern characteristic for HR^{36,37}. The majority of cells were killed within the first 2 h of treatment, whereas a resistant subpopulation arose between 4 and 24 h and grew to levels comparable to the resistant phenotype (Fig. 1C). HR is further characterised by its reversibility: in the absence of the stressor (in this case, the antibiotic CAZ), the entirely resistant subpopulation reverts back to an almost susceptible population¹⁴. To determine whether this phenomenon also holds true for ECC IMT 49658, we subcultured ten individual resistant colonies on blood agar plates without antibiotic over the course of 3 weeks. The diameter of the inhibition zone on MH II agar plates were determined in parallel (Supplementary Fig. S1). As depicted in Fig. 1D, all ten resistant replicates revert back to a susceptible phenotype with distinct inhibition zone diameters. Interestingly, all ten replicates showed varying degrees of reversal at the end of the experiment, confirming the heterogenetic nature of this phenomenon (Fig. 1D).

Finally, we asked whether the resistance determinant underlying the resistant phenotype is associated with a fitness loss, as was often observed³⁸. Indeed, the resistant phenotype in the ECC isolate appeared to confer a fitness disadvantage in the absence of antibiotics as determined *via* competition assays. Here, the ECC source population outcompeted the resistant phenotype with competition indices of 1.69, 2.03 and 2.64, after 8, 24 and 48 h of competition, respectively (Supplementary Fig. S8).

Proteomic and genomic analysis reveals high similarities between resistant phenotype and ECC source population

To clarify the mechanisms underlying the heteroresistant phenotype, we performed quantitative proteome analysis of both an isolate of the resistant phenotype (originating from the CAZ zone of inhibition) and its parental strain (hereafter referred to as ECC susceptible source population) using liquid chromatography-mass spectrometry (LC-MS). Compared to the ECC source population, six proteins were down- and fourteen were up-regulated in the resistant phenotype (Fig. 2A, List of proteins added in Supplementary Fig. S2). Intriguingly, the AmpC-type β -lactamase *bla*_{DHA-1} gene product and *ampC* transcriptional regulator AmpR were both up-regulated in the resistant phenotype. This is consistent with the observations that avibactam suppresses the occurrence of inhibition zone colonies in an Epsilon (E-test): Avibactam is a broad spectrum, non- β -lactam inhibitor of both class A- and C-type β -lactamase and has been shown to increase the efficacy of CAZ in over-producing isolates and at high bacterial inocula³⁹ (Supplementary Fig. S3).

We next performed a genomic analysis of both the resistant phenotype and the ECC source population after Illumina and Oxford Nanopore sequencing. In both, the resistant phenotype and ECC source population, whole-genome sequencing (WGS) confirmed the presence of class A β -lactamases *bla*_{TEM-1} and *bla*_{CTX-M-3}, as well as AmpC β -lactamases, *bla*_{ACT-16} and *bla*_{DHA-1}. In addition, Nanopore-sequencing revealed that *bla*_{DHA-1} and the two class A β -lactamases were localised on a \approx 290 kbp large IncHI2/2A plasmid, whereas *bla*_{ACT-16} was located on the chromosome. A direct comparison between the ECC source population and the resistant phenotype using the Geneious mauve alignment tool revealed a genetic identity of 99.68% (Fig. 2B). Further, variant calling with Snippy identified no SNPs in genes associated with antibiotic resistance to cephalosporines, such as *ampD* or the promoter regions of AmpC β -lactamases, that might explain the resistant phenotype^{40,41}. Both proteomic and genomic data therefore indicated that the HR phenotype was linked to *bla*_{DHA-1} expression but was not due to point mutations in the known resistance genes. Using targeted mutagenesis, we deleted the *bla*_{DHA-1} gene and performed agar-disk diffusion as described above. The isogenic Δ *bla*_{DHA-1}-mutant of the ECC source population completely lost its ability to form individual colonies within the inhibition zone and showed no HR on a PAP-Assay according to the definition of Band et al.³⁶ (Supplementary Fig. S4B2, B3). The same result occurred in four replicates of ECC IMT 49658 with the deletion of two regions (\sim 51.4 kbp and \sim 13.6 kbp) of the IncHI/2 A plasmid after




Fig. 1 | Phenotypic characterisation of heteroresistance (HR) in *Enterobacter cloacae* complex (ECC). **A** In the presence of ceftazidime (CAZ) the source population of ECC exhibits a heteroresistant phenotype (left) in agar-disk diffusion with susceptible population (outside inhibition zone, beige bacteria) and single colonies within the inhibition zone (black bacteria, resistant subpopulation). Suspending an inhibition zone colony to McFarland standard density and re-plating it results in a resistant phenotype (right). **B** Population analysis profile (PAP) of the source population of ECC (beige) meets the criteria for HR with cell growth on antibiotic plates with 2- or 4 fold breakpoint concentration (blue circle). The size of the resistant subpopulations (y axis, \log_{10} scale) on plates with increasing antibiotic concentrations (x axis) is plotted with mean and SD of colony count of three biological replicates. The resistant phenotype preserves its population successfully (black). **C** Time kill assay with

\log_{10} survival in percent (y-axis) of the resistant (black) and heteroresistant phenotype (beige) over the course of 24 h (x-axis) at 4 × MIC (6 µg/ml CAZ) of the susceptible source population. Values are indicated with mean and SD of three biological replicates. In contrast to the resistant phenotype, the heteroresistant phenotype requires the selection of resistant subpopulations (4–6 h) prior to population growth. **D** Replicates ($n = 10$, black lines) of the resistant phenotype of the *Enterobacter cloacae* complex lose their resistance by subcultivating individual colonies every day (x-axis) on blood plates without CAZ after overnight incubation. The diameter of the inhibition zone (y-axis) of the subcultured replicates was measured using agar-disk diffusion assays. Black dots indicate final measurements of each replicate; horizontal lines indicate the size of the inhibition zone of the ECC source population (blue) and the resistant subpopulation (orange).




Fig. 2 | Genetic background of heteroresistance in *Enterobacter cloacae* complex (ECC). **A** Volcano plot of the relative changes in protein signal intensity between the resistant phenotype (right side) and the original ECC source population in the absence of CAZ (left side). Significant protein hits ($p < 0.05$) showing at least a 2-fold change in their relative intensity are marked with blue and red dots. A list of all significant protein hits is shown in Supplementary File 1, Fig. 2. **B** Ring comparison of the complete genomes from resistant phenotype (red) and ECC source population (grey), including coding sequences (CDS, light blue), rRNA (orange) and GC-content (black). Each genomic region of the resistant phenotype has a corresponding region in the ECC source population. **C** Fold change gene expression in the resistant phenotype of 4 different β -lactamases (*bla_{DHA-1}*, *bla_{ACT-16}*, *bla_{CTX-3}*, *bla_{TEM-1}*) and two corresponding transcriptional regulators (*ampR/bla_{DHA-1}*, *bla_{ACT-16}*) relative to the ECC source population. qPCR results from cDNA were plotted with mean and

IQR from $n = 6$ replicates per gene. *Bla_{DHA-1}* and its transcriptional regulator is predominant in the resistant phenotype representing inhibition zone colonies. **D** Mapping of Illumina reads to the reference sequence of plasmid IncHI2/2A reveals a high coverage (blue) for ~ 17 kbp gene region around position 220,000. **E** The 17 kbp long fragment contains *ampR* and *bla_{DHA-1}* (blue circle) and is amplified in a concatenate manner, confirmed in Oxford MinIon nanopore long read sequencing. The red arrows represent the start of a new gene duplication-amplification (GDA). **F** Fold change copy number in the resistant phenotype of 4 different β -lactamases and two corresponding transcriptional regulators relative to the ECC source population shows a higher copy number for genes from the GDA (*bla_{DHA-1}* and its *ampR*), acquired from qPCR with genomic (g)DNA. Median and IQR of $n = 6$ replicates per gene is plotted.

prolonged incubation at high temperatures⁴², which led to the elimination of *bla_{DHA-1}* (Supplementary Fig. S4A1, A2). These results finally confirmed that *bla_{DHA-1}* is responsible for the heteroresistant phenotype of ECC IMT 49658.

AmpC β -lactamase *bla_{DHA-1}* is amplified within a 17 kbp large gene fragment on the IncHI2/2A plasmid causing HR in ECC

Consistent with the proteomic data, the expression levels of the transcriptional regulator *ampR* and of *bla_{DHA-1}* were 16.37-fold and 47.9-fold higher in the resistant phenotype than in the ECC source population, respectively (Fig. 2C). In contrast, the fold change differences for the three additional β -lactamases, including two ESBL, were negligible. In order to explain the increased expression of *AmpR* and *bla_{DHA-1}*, we hypothesised that GDA events might be responsible for the differences in gene expression. Closer inspection of the genome sequencing data from the resistant phenotype showed a higher sequence coverage for a 17 kbp region on the IncHI2/2A plasmid harbouring genes encoding proteins previously identified as up-regulated in the proteomics data, including *bla_{DHA-1}*, *qnrB* and the *psp* and *sap* operons (Fig. 2D, E). We confirmed the higher coverage by analysing Nanopore long reads, displaying GDA of the 17 kbp region and using genomic DNA in qPCR. (Fig. 2F). Here, the apparent copy numbers of *ampR* and *bla_{DHA-1}* were

between 8.5 and 8.7 times higher in the resistant phenotype than in the ECC source population, respectively. MinION nanopore long read sequencing (Oxford Nanopore Technologies) confirmed that both *bla_{DHA-1}* and its associated *ampR* gene were located on the same GDA region that was flanked by *qacE/sul1* on both sides (Fig. 2E). Additionally, qPCR results of five other genes within the GDA region from independent HR isolates demonstrated similar increased copy numbers within the 17 kbp region (Supplementary Table S3). Since the formation of GDAs can occur in a *recA* dependent or independent manner^{43,44}, we subsequently generated a targeted, *recA* deficient ECC mutant strain. When growing a $\Delta recA$ mutant of the ECC source population overnight in 16 $\mu\text{g/ml}$ CAZ, no GDAs were detected in qPCR, suggesting that the establishment of GDAs in the ECC is a *recA*-dependent mechanism (Supplementary Fig. S4C1, C2).

Resistant subpopulations exhibit colony- and growth variability linked with the copy number of gene-duplication-amplifications (GDA) that vary on a single cell level

Next, we speculated about a direct interdependency between gene copy number, expression of resistance and growth behaviour of resistant subpopulations, because we made the observation that independent colonies within the inhibition zone harbour different amounts of GDAs.




Fig. 3 | Growth variability of resistant subpopulations via gene duplication-amplification (GDA) copy number. **A** GDA-copy-number of 9 inhibition zone colonies (IZC) from agar-disk diffusion with CAZ differs between each IZC. qPCR was used to assess GDA copy number with gDNA. The graph displays median (bars) & interquartile ranges (IQR) (error bars) of three technical replicates of *ampR* and *bla_{DHA-1}* per IZC. Dots indicate specific values of technical replicates for *ampR* and *bla_{DHA-1}* genes. $2^{\Delta\Delta\text{ct}}$ values of IZCs represent relative fold change values to cell material outside the inhibition zone. **B** For GDA-copy-number (y-axis) and inhibition zone-size (table at the bottom) of eleven different resistant subpopulations (red bars), a negative correlation (spearman correlation coefficient $r = -0.94$, $p < 0.0001$, CI -0.98 to -0.76) was detected (see inset). **C** GDA-copy-number heterogeneity in reads from Oxford Nanopore MinIon sequencing of a single IZC. Blue bars indicate copies, orange lines represent spanning reads, displaying the entire GDA and genome-areas beyond. Numbers on the right of non-spanning reads indicate the read-amount with the respective GDA-copy-number. Copy-numbers

are shown on the left. **D** Area (y-axis) of single colonies (lines) as a function of time (x-axis) for the ECC source population (red shading) without CAZ and with 32 $\mu\text{g/ml}$ CAZ, representing resistant subpopulations (yellow shading) in ScanLag. ECC source population shows homogeneous lag times on plates without antibiotics but heterogeneous lag times when grown on 32 $\mu\text{g/ml}$ CAZ, revealing resistant subpopulations. **E** Fold-change GDA-copy-number relative to the ECC source population, presented by $n = 5$ single colonies in ScanLag emerging early (dark red bars) and $n = 6$ colonies growing late (light red bars) on plates with 32 $\mu\text{g/ml}$ CAZ. CFUs with short lag times have more GDAs than late occurring CFUs. No GDAs occur in CFUs from antibiotic-free plates (blue bars, $n = 5$). **F** CFU size over time, each line represents one CFU. Line colours represent the GDA-copy-number per CFU as defined by the colour scale. Solid lines are resistant CFUs growing on 32 $\mu\text{g/ml}$ CAZ plates in ScanLag. Dashed lines are controls of the source population grown without CAZ.

To address this question, we picked nine independent colonies from within the inhibition zone that occur in variable sizes and at different distances from the CAZ-disk (Fig. 1A, Supplementary Fig. S5). Subsequent qPCR analysis revealed GDA levels ranging from ~9 to ~29 copies (Fig. 3A, Supplementary Fig. S5 and Supplementary Table S4). Moreover, for eleven different resistant subpopulations from the above mentioned reversal experiments, a negative correlation between GDA copy number and the diameter of the inhibition zone was confirmed by qPCR using gDNA templates (Fig. 3B & inset, Spearman coefficient $\rho = -0.94$; $p = < 0.0001$). To determine whether variability in GDA copy number also exists within a single inhibition zone colony, we analysed the GDA copy number in single MinION nanopore raw reads from inhibition zone colonies, using 5 replicates. To display the highest GDA copy number possible in the length-limited nanopore raw reads, we shortened the GDA via Wanner mutagenesis from 17 kbp to 7 kbp. As the nanopore sequencing generates sequence data from individual input DNA molecules without prior PCR amplification steps, gene copy number differences reflect differences present within a resistant colony^{45,46}. Astonishingly, each colony revealed highly heterogeneous copy number distributions of GDAs, as shown for one colony (Fig. 3C). There were the entire GDA spanning raw reads from the same colony, displaying one but also five GDAs. The maximum GDA copy number detected was six. In another inhibition zone colony a maximum of 16

GDAs were detected and spanning reads with one GDA occurred (data not shown). This emphasises the enormous range of variation even within a single colony and demonstrates that genotypic plasticity extends to single-cell level.

Next, we asked how the observed GDA variability between and within colonies is related to growth under antibiotic CAZ pressure. To quantify colony appearance and growth arising from single-cells we used ScanLag to perform time-lapse imaging on agar plates⁴⁷. We observed increased heterogeneity among resistant subpopulations in lag times of colony appearance, growing on antibiotic-containing plates (interquartile range (IQR) 693–984 min), whereas the ECC source population displayed homogeneous lag times (IQR of 483–499 min.) in the absence of CAZ (Fig. 3D, Supplementary Fig. S6). qPCR analysis of genomic DNA of the colonies showed that early emerging colonies exhibited more GDAs than late emerging colonies in the presence of CAZ (Fig. 3E, F). To distinguish between subpopulations with long and short lag times, we chose a cut-off of 814 min., the median of the lag time of the resistant subpopulations. The average GDA copy number for colonies with short lag times was 21.49, whereas the average copy number for colonies with long lag times was 13.88 (Fig. 3E, unpaired students *t*-test $p < 0.0001$). Colonies harbouring high GDA numbers not only had shorter lag times (earlier onset of growth and therefore faster doubling), but also grew faster and accelerated growth more rapidly compared to colonies with lower GDA number (Fig. 3F).

Surprisingly, despite their early onset of growth (short lag times), the growth rates of colonies growing without CAZ (green dashed lines in Fig. 3F) were relatively slow (lower slopes). In addition, they did not accelerate (curvature) as strongly as colonies with high GDA numbers that grew under CAZ exposure (Fig. 3F).

Statistical modelling reveals a highly complex interplay between GDA, lag time and antibiotic treatment on growth of resistant sub-populations

Our observation that GDAs vary at the single cell level finally raised the question how lag time of colony appearance, colony growth and GDA number interact under CAZ exposure. To quantify these interactions, we fitted curvy-linear models that took GDA copy number, lag time and CAZ treatment as additive or interactive explanatory factors and colony growth of resistant subpopulations as response variable into account (Supplementary Table 7). The data we used were the ScanLag growth data described earlier (Fig. 3F). Comparing a first set of generalised linear models revealed that colony growth differed in their growth acceleration with time (comparing Model 1 that fixes growth acceleration to model 2 that allows for different acceleration of growth) (Supplementary Table 7). In addition, antibiotic treatment, lag time and amplification number not only simply added to explain variance among growth curves but all showed differences in growth acceleration. This implies that growth (slopes) and growth acceleration (curvature) differ with increased GDA copy number, that colony growth characteristics also differ between CAZ and CAZ free conditions and that growth rates and acceleration of growth differed among colonies with different lag times. All of these three effects, treatment, copy number or lag time, contributed to the differences in growth and growth acceleration and none of them was redundant. Combined, these statistical model comparisons highlight, by quantitative statistical support, the complex interplay between GDA, lag time and treatment (CAZ pressure), driving heterogeneity in growth of resistant subpopulations.

Discussion

This study revealed HR to the third generation cephalosporine, CAZ in an *Enterobacter cloacae* complex (ECC) strain based on population plasticity originating from a GDA mechanism. Resistant sub-populations exhibited a high degree of resistance levels and a reversal of resistance after antibiotic withdrawal. We demonstrated that the molecular process of the heterogeneous phenotype is facilitated by the transient, unstable character of a plasmid-localised GDA of the AmpC-type β -lactamase *bla*_{DHA-1}. The underlying genomic plasticity due to variable copy numbers of GDAs was detected at colony and even the single-cell level within purified bacterial colonies, and we examined the associated heterogeneity in fitness costs by exploring growth patterns and in competition assays.

The results highlight the problematic detection of HR which is complicated by the extent of heterogeneity among resistant subpopulations. Diverse bacterial strategies exist in response to antibiotic stress, e.g. mutations⁴⁸, transcriptional regulation of stress related genes⁴⁹, plasmid multiplication⁵⁰ and GDA⁵¹. An additional phenotypic effect of *bla*_{DHA-1} due to increased copy number of the IncHI2/2A plasmid was ruled out since both resistant and susceptible ECC source population contained one plasmid copy per cell (Supplementary Fig. S7, Supplementary Table S5). Various molecular mechanisms enable cell-to-cell variations. Examples include stochastic variation of transcription factors and epigenetic changes or phase variation of certain gene loci⁵². For example, phase variation has similar mechanisms as GDA formation, but is mainly associated with an 'ON or OFF' state regarding the expression of a distinct phenotype^{52,53}. The same applies for epigenetic switches concerning virulence of bacteria⁵⁴⁻⁵⁶. In conclusion, most of these mechanisms lack the fine-tuned evolutionary plasticity GDAs allow for.

The mechanisms underlying GDA are still a matter of debate. In addition to theories regarding unequal crossing over between homologous regions of sister chromosomes and the dependence or independence on recombination, the role of mobile elements and phenomena like strand

slippage, tandem inversion duplication and single-strand annealing are discussed^{43,44}. In many cases, GDAs are associated with direct repeated homologous areas flanking the GDAs^{43,51,57,58}. We found for resistant subpopulations of ECC that the 17 kbp amplification of the plasmid was flanked by *qacE/sulI* (Fig. 2E). *QacE/sulI* has been previously found in chromosomal GDA of *S. Typhimurium*^{25,35}. In contrast, other authors have also demonstrated GDAs of varying lengths⁵⁹⁻⁶¹ without considerable homologous regions. Those GDAs are discussed with initially random and RecA-independent mechanisms including ligation of DNA ends via gyrase activity⁶², strand slippage⁶³, or pairing of single stranded regions⁶⁴ and subsequent RecA-dependent amplification between homologous areas provided by the initial duplication⁴³.

We confirmed GDA as the determining factor for CAZ HR in an ECC isolate using both genome sequencing (Illumina MiSeq and MinION technologies) and qPCR methods (Fig. 2B-F, Fig. 3A-C, E), and further showed that the underlying factor for growth heterogeneity is the varying copy number of GDAs (Fig. 3D-F). Previously, heterogeneity of resistant subpopulations has been shown in PAP assays¹³ by quantifying resistant subpopulations using increasing antibiotic concentrations, but these studies did not include growth data of subpopulations. In our study, using single colony ScanLag data, we were able to show that there is a wide phenotypic diversity regarding cell growth when the original population is exposed to CAZ, even at a single antibiotic concentration (Fig. 3D + F, Supplementary Fig S6). The distribution of GDAs not only varied between heteroresistant colonies, but also within single cells of a single, resistant colony based on nanopore sequencing data from single colonies (Fig. 3C). These findings align with previously shown cell-to-cell GDA-copy number heterogeneity of *lepB* upon arylomycin treatment in clonal populations of *E. coli* and *A. baumannii*⁴⁶. The limiting factor to prove GDA copy number heterogeneity per raw read are the length of the raw reads. Only in both sides spanning reads, the number of GDA copies can be adequately detected. Remarkably, every single GDA dosage per cell translated into many different growth phenotypes in ECC resistant subpopulations with different scenarios on fitness. Fitness loss has previously been shown for GDA-driven HR^{25,31}. Consistent with this, we also confirmed a fitness loss in competition assays for the GDA-containing resistant subpopulation in an antibiotic free environment (Supplementary Fig. S8). However, the fitness cost of resistance might not be high, as under experimental conditions comparing colony growth on antibiotic-free plates separately, the resistant phenotype and ECC source population showed no growth or lag time differences (Supplementary Fig. S9 and Supplementary Table S6). Within resistant subpopulations in a homogeneous antibiotic condition, bacteria with a higher number of GDAs and hence a greater level of resistance, out-competed those with fewer GDAs (Fig. 3F). In the presence of antibiotics, therefore, increased GDAs do not appear to confer a fitness disadvantage. Further studies need to evaluate when GDA leads to a fitness disadvantage as described in the literature⁶⁵.

Another hallmark of HR and GDA are their often reversible phenotype and transient genotype(s). In this study, we showed that not only the selection but also the reversal of GDA-driven resistant subpopulations is highly dynamic (Fig. 1D). Generally, the transience of resistant subpopulations has only been demonstrated in liquid culture, representing the average reversal at a population level^{25,31,35}. Here, we performed the resistance reversal experiments with single colonies originating from single bacteria on agar plates to examine loss of resistance at a subpopulation level.

As already shown for the closely related species *E. coli* and *Salmonella enterica*, respectively, the reversal of resistance is due to two factors: (1) The fitness burden of GDAs, which has been estimated to result in a fitness loss of 0.15% per DNA kilo base pairs in *E. coli*⁶⁵ and (2), the inherent instability of GDAs due to deletional processes during the formation of GDAs³³ which was estimated to have a mechanistic rate of 0.15/generation/cell in *Salmonella enterica*⁶⁶. Thus, a successful reversal in antibiotic-free environments is dependent on the mechanism of GDA formation itself and the competition between those resistant cells with GDAs and less resistant cells which have lost GDAs. Such a competition may be higher in liquid media in which

single cells are confronted with a large population of competing cells compared to assays examining individual, isolated cells after growth on plates where competition is limited to cells within one colony. Although no such specific values can be found for the genus *Enterobacter*, the shared affiliation to the family of *Enterobacteriaceae* and the close relationship to the genera *Escherichia* and *Salmonella* may explain the relatively long reversal time shown by some of the ECC resistant phenotype-replicates (Fig. 1D).

In our study we show, how antibiotic treatment, GDAs and lag times of single colonies influence the growth of resistant subpopulations through complex interactions (Supplementary Table S7). Such complexity challenges simple eradication of resistant subpopulation in clinics. Model comparison allowed us to evaluate the importance of the factors (lag time, treatment, GDA), with GDAs having the major impact on the heterogeneous, accelerated growth of resistant subpopulations (Supplementary Table S7). Consequently, GDA comprises a powerful strategy for ECC to survive antibiotic exposure. Within the host, additional variables may further influence resistant subpopulations' growth behaviour. Nevertheless, our findings suggest treatment protocols against heteroresistant infections should focus on the minimisation of GDA triggering conditions in order to prevent accelerated growth of resistant subpopulations. In fact, initial results on this can be found in the literature: Gullberg and Pereira were able to show in their studies using *E. coli* and *S. enterica* as model organisms, that antibiotic concentrations below the so-called minimal selective condition (MSC) prevent the selection of GDA-bearing resistant subpopulations. However, it should be noted here that this strategy only works if the MSC is above the MIC of the source population. Otherwise, there would be no therapeutic effect. Finally, antibiotic combinations have been shown to successfully control heteroresistant infections. In a recent study, Band and colleagues impressively showed that antibiotics that had been shown to be harmful when used alone had additive effects when used in combination, leading to the complete eradication of pan-resistant *Klebsiella pneumoniae* strains. Such studies are of enormous importance, especially for clinical questions, as they can provide important information for a promising approach to the ever-worsening antibiotic resistance crisis³⁶.

In summary, our studies on the gain and loss of GDAs demonstrate a GDA-driven population dynamics for a heteroresistant ECC strain and revealed traits involved in bacterial plasticity and fitness. In the absence of effective detection and treatment protocols for HR^{13-15,35}, we believe our findings further emphasise the need for developing a heightened awareness of the phenomenon of HR among clinical isolates and further studies towards their efficient detection and treatment.

Materials and methods

Strains, media and antibiotics

The bacterial strain used in this study is a clinical ECC IMT49658-1 isolated from the wound of a horse in the equine clinic of the department of Veterinary Medicine at the Freie Universität Berlin (NCBI bioproject number: PRJNA1020684, biosample number: SAMN37527804, accession numbers CP135270-CP135274). Bacterial identification was performed with Vitek2 (GN-card) and via matrix-assisted laser desorption/ionisation-time of flight mass spectrometry (MALDI-TOF MS)-based identification with Bruker ultrafleXtreme in combination with flexControl (Version 3.4) and MBT Compass (Version 4.1) software (Bruker Daltonics, Billerica, MA, USA). In order to ensure clonality of the strain, a clearly isolated colony was the origin of the frozen stock. Additionally, species identification of the ECC IMT49658-1 isolate was done with WGS-data of this stock using ribosomal Multi Locus Sequence Typing (rMLST)⁶⁷ and PubMLST (<https://pubmlst.org/species-id>), resulting in a 100% match for *Enterobacter hormaechei*.

IMT49658-1 defines the original ECC source population. In the presence of CAZ it exhibits a heteroresistant phenotype with susceptible and resistant population entities. The resistant phenotype IMT49658-3 represents these resistant subpopulations. For further investigations 9, additional inhibition zone colonies and 4 heat treated isolates were used of these strains (Supplementary Table S2). Cation-adjusted Mueller-Hinton II (MH II) agar

and broth (Becton Dickinson and Company, Sparks, USA) was used for antibiotic resistance testing and LB broth (Lennox formulation; Carl Roth, Karlsruhe, Germany) for most other experiments. Unless noted otherwise, incubation of cultures was at 37 °C. CAZ was used from Sigma-Aldrich (St. Louis, USA). Heat treatment plasmid-curing was performed in brain-heart-infusion (BHI) media (Carl Roth, Karlsruhe, Germany), and CHROMagar™ (Mast Diagnostica GmbH, Paris, France) plates. Columbia blood agar (5% sheep blood) (Becton Dickinson and Company, Sparks, USA) was used in reversal of resistance experiments.

E-tests and agar-disk diffusion assays (antimicrobial susceptibility testing)

E-tests were performed with IMT49658-1 and IMT49658-3 with CAZ and CAZ-Avibactam combination (Biomérieux, Marcy-L'Étoile, France). Agar-disk diffusion method was conducted with CAZ (Becton Dickinson BBL™ SensiDisc™, Sparks, USA) for IMT49658-1, IMT49658-3, IMT49658-1ΔcatA2ΔblaDHA-1, IMT 49658-1ΔcatA2ΔrecA, IMT49658-1ΔcatA2GDAs_{short} and additionally with 12 colonies after heat treatment. For both antimicrobial susceptibility tests a bacterial density of McFarland standard 0.5, adjusted in NaCl, was incubated on MH II plates for 16–20 h at 35 °C according to CLSI VET01 (performance standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria isolated from Animals).

Isolation of the resistant subpopulation

The suspension of a single inhibition zone colony from agar-disk diffusion assay to McFarland standard 0.5 in NaCl was streaked on a MH II plate and subsequently incubated with CAZ disk as described in the section ('antimicrobial susceptibility testing') above.

Population analysis profile (PAP)-Assay

Exponential phase cultures (OD_{600nm} 0.5) of IMT49658-1, IMT49658-3 and a heat-cured isolate IMT49658-3_27x_P29 were set to a density of 10⁸ CFU/ml and subsequently diluted in 1 × PBS in 1:10 dilution steps until 10³ CFU/ml. 100 μl of appropriate diluted bacterial suspension were homogeneously applied to MH II plates with double increasing antibiotic concentration of CAZ, using triplicates for each concentration. Considering El Halfawy and Valvano's suggestion¹³, we used a multiple concentrations of the breakpoint of CAZ, 16 μg/ml CAZ for *Enterobacteriales*⁶⁸ (Table 2A from ref. 68), resulting in 0, 2, 4, 8, 16, 32, 64, 128 and 256 μg/ml CAZ. Plates were incubated at 37 °C for 48 h and subsequently colonies were counted. After extrapolation of the chosen dilution the colonies were plotted in log₁₀ CFU/ml on the y axis against the antibiotic concentrations on the x-axis. Assessment of HR was done by criteria of both, El Halfawy and Valvano¹³ and Band et al.³⁶.

Time-kill assays

Time-kill assays were conducted in 6 ml LB (Lennox) for IMT49658-1 and IMT49658-3 with 4-fold the MIC-concentration of CAZ for IMT49658-1, previously determined in E-tests. Note, that a MIC is not detectable in liquid broth-based MIC-assays for heteroresistant cultures, because the resistant subpopulation overgrows the initially major susceptible population. The inoculum preparation consisted of bacteria grown to exponential phase (OD_{600nm} of 0.5) adjusted to 10⁷ CFU/ml. After addition of the antibiotic at timepoint 0, bacteria were incubated at 37 °C and 200 rpm. Survival of bacterial cells were determined in triplicates in intervals of 2, 4, 6, 18 and 24 h after starting the experiment. To this end, aliquots were washed by centrifugation in order to remove antibiotic and the bacterial cell pellets were resuspended in 1 × PBS and diluted in 1:10 steps before plating. Cell counts were performed after 24 h incubation at 37 °C and values were plotted as percentage of the population at timepoint 0 (y-axis) against time (x-axis).

Heat-treatment of IMT49658

Heat treatment aiming for plasmid curing was performed essentially as described by Schaufler et al.⁴² with some modifications. Briefly, heat treatment was performed with overnight cultures of IMT49658-1 and

IMT49658-3 separately, incubating at 45 °C overnight in 5 ml BHI broth in a static, non-shaking manner. After every overnight incubation, 100 µl from the respective strain were transferred into fresh BHI broth and the incubation at 45 °C was repeated as described above. After every passage, a 1:10 or 1:100 diluted aliquot of ~10 µl was placed on a CHROMagar™ plate and incubated at 37 °C overnight. Next, single colonies were picked and placed on a CHROMagar™ plate with 25 µg/ml kanamycin and without kanamycin and incubated again overnight at 37 °C. The absence of kanamycin resistance indicates a possible heat disruption of the plasmid, because kanamycin-resistance-genes in IMT49658 are only localised on the plasmid and not on the chromosome. CHROMagar™ plates were used because they detect contamination directly by colour of the CFU. CFU's not growing on plates with kanamycin were double checked by re-incubating on plates with kanamycin. Confirmed non-growers were further investigated for plasmid disruption with PCR using primers for *bla*_{DHA-1} and *bla*_{CTX}, both localised in the IncHI2/A plasmid.

PCR for *bla*_{DHA-1} and *bla*_{CTX} in heat-treated CFU

PCR for genes of IncHI2/2A plasmid with colonies of heat-treated IMT49658 was performed with Promega GoTaq DNA Polymerase (M300) Protocol including the 5 × Green GoTaq® Reaction Buffer 1 (7.5 mM MgCl₂). 1 µl of sample DNA was added to 49 µl Mastermix and 35 cycles of predenaturation (95 °C 180 s), denaturation (95 °C, 60 s), annealing (55 °C, 60 s), elongation (72 °C, 60 s) and endelongation (72 °C, 300 s) were performed.

Reversal of resistance/stability analysis of antibiotic resistance

The resistant phenotype IMT49658-3 (resistant subpopulation) was streaked on columbia blood agar plate (with 5% sheep blood) and incubated over night at 35 °C (<18 h). A McFarland standard density of 0.5 was set in NaCl for each of ten individual colonies (replicates) from the blood plate and separately spread on MH II plates performing an agar-disk diffusion with CAZ as mentioned in the method section 'antimicrobial susceptibility testing'. From the same McFarland suspensions, a single loop was streaked out on a blood agar plate for each replicate and incubated overnight at 35 °C together with the agar-disk diffusion plates. Next, after 16–20 h inhibition zones were measured and photographed. The reversal continued for each of the ten replicates by picking one single colony from blood agar, repeating the above-mentioned procedure over 21 subcultivations. Subcultivations were only conducted with colonies from blood agar without antibiotics, ensuring the chance for reversal. Daily agar-disk diffusion provided information for the current status of resistance of each replicate. An overview of the method provides Supplementary Fig. S1.

Competition assays of resistant and heteroresistant phenotypes

Measurement of the competition assays between resistant (IMT49658-3) and ECC source population (IMT49658-1) were performed with both strains in one batch, competing for the same nutrients. A neomycin-cassette comprising plasmid pProbe'-gfp (LAA)⁶⁹ (Addgene Cat. Nr. 40171) with mScarlet, a red fluorescence protein with a constitutive pnptII promoter, was used for distinguishing both phenotypes. Consequently, it was possible to distinguish both phenotypes by growth on neomycin and by colour of the colony (red). To constitute this plasmid-construct, we amplified mScarlet from plasmid pMRE135 and introduced it into pProbe'-gfp (LAA) between restriction sites NheI and EcoRV. In order to control for possible inference of the plasmid with growth, we used two competition assays at one time, one with pProbe'-gfp (LAA)+mScarlet in IMT49658-1 and a second one with the same plasmid in IMT49658-3. In parallel, two control assays were performed with plasmid containing either in IMT49658-1 or IMT49658-3 alone in order to detect plasmid loss over the course of the experiment in non-antibiotic containing media.

The competition assays were incubated at 37 °C, 200 rpm in 6 ml LB (Lennox) broth. Competition was measured by cell-count after 0, 8, 24 and 48 h. The starting inoculum for both strains were 200 µl of 2 × 10⁶ CFU/ml. After every time point, an aliquot of bacterial suspension was

centrifuged and the remaining pellet was resuspended in PBS. Bacteria were plated at an appropriate dilution performed in 1 × PBS using a volume of 100 µl on plates (triplicates) with and without neomycin. Lastly, calculation of CFU on plates with and without neomycin after 24 h in 37 °C was used to calculate competitive index (CI) using the following formula: $CI = (IMT49658-1 \text{ output}/IMT49658-3 \text{ output}) / (IMT49658-1 \text{ input}/IMT49658-3 \text{ input})$.

Growth analysis for resistant subpopulations with ScanLag

Experimental set-up. ScanLag experiments to determine lag times and growth rates of single colonies were performed as described by Levin-Reisman et al.^{47,70}. To assess fitness loss between GDA carrying—and non-carrying isolates, experiments were conducted with IMT49658-1 and IMT49658-3 using MH II plates without CAZ. ScanLag experiments for resistant subpopulations were performed with IMT49658-1 on MH II plates with 32 µg/ml CAZ (2x breakpoint concentration of CAZ for *Enterobacterales*⁶⁸ (Table 2A from ref. 68)). Here, only resistant subpopulations manage to grow and the majority of susceptible bacteria of IMT49658-1 do not grow.

Strains were grown from single colonies in 10 ml MH II broth at 37 °C and 200 rpm to exponential phase (OD_{600nm} 0.5) and diluted to 10³ CFU/ml before plating 100 µl of the bacterial suspension uniformly on MH II plates for experiments without CAZ. For experiments with CAZ, bacterial suspensions with 2.5 × 10⁷ CFU/ml were established and 100 µl of the suspension was uniformly plated on MH II plates with 32 µg/ml CAZ. Subsequently, plates were placed in plateholders of all scanners (Epson perfection V370 photo). For optimal contrast and absorption of moisture, sterile black felt cloth was placed between the plates and the plate lids as described in ref. 47. Incubation was performed at 33 °C due to the temperature resilience limitation of scanners. Scanners were controlled by the custom software UnixScanningManager (<https://github.com/nirda/UnixScanningManager>, commit 5d94cd3) on a Linux operating system (Ubuntu 20.04 LTS AMD 64). After an initial waiting time of 240 min, plates were scanned every 15 min. Incubation and image acquisition was done for 24 h.

Data analysis. Subsequently, images were analysed in Matlab R2020a (MATLAB. (2020).version 9.8.0.1396136 (R2020a). Natick, Massachusetts: The MathWorks Inc.) using a custom script incorporating previously published analysis image software NQBMatlab(<https://github.com/offerfrid/NQBMatlab/tree/V16>, commit 65306ce)⁴⁷. Image analysis results were curated manually and, after removal of segmentation artifacts, exported to Microsoft Excel, providing information to appearance - and growth time^{47,70} per colony. Supplementary Fig. S6 was plotted with GraphPad Prism version 8.4.3 (686) for Windows, GraphPad Software, San Diego, California USA, www.graphpad.com.

The colony appearance time (lag time) is defined as the time at which a colony reaches the detection threshold area of 10 pixels. Growth times are defined as the time a colony needs to increase its area from 15 to 45 pixels (Supplementary Fig. S9 and Table S6). More detailed analyses of the growth data were done in programme R Core Team (2023). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <https://www.R-project.org/>. (Fig. 3C, Supplementary Table S7). To evaluate growth of single colonies, considering colony growth as change in area respectively pixel/time, (Fig. 3C, Supplementary Table S7), we right censored cells that merged during their growth and therefore used different definitions than the NQBMatlab definitions that exclude these cells⁴⁷. Colonies that increased in pixel size of >1.5 times per 15 minutes and at the same time had at least 30 pixels were assumed to have merged and their growth was—after merging—right censored (i.e. data was excluded from merging onwards). Plotting of graphs (Fig. 3C) was done using R library ggplot2, Wickham H (2016). *ggplot2: Elegant Graphics for Data Analysis*. Springer-Verlag New York. ISBN 978-3-319-24277-4, <https://ggplot2.tidyverse.org>.

Proteomics

Proteomic analysis was conducted with ECC source population (IMT49658-1) and resistant phenotype (IMT49658-3) each with 5 replicates. Initially, cell lysis with 20 mM ice-cold HEPES buffer was performed on pellets from exponential phase culture. A sonification step (UP100H; Hielscher Ultrasound Technology, Teltow, Germany) induced mechanical cell disruption, using a duty cycle of 1.0 and an amplitude of 100% for 45 s. In the next step in-solution trypsin digestion with 5 µg of total protein for each sample was carried out with the protocol of Wareth et al.^{71,72}.

Nano LC-MS and data analysis was performed with derived peptides with an Ultimate 300 reversed-phase capillary nano liquid chromatography system attached to a mass spectrometer (Orbitrap Q Exactive HF, Thermo Scientific). Mass spectra's raw data were analysed by MaxQuant software package version 1.6.14, including the Andromeda peptide search engine⁷³. Default settings of MaxQuant were used except for label free quantification (LFQ) and match between runs (MBR). First, data were searched against the custom database for ECC with 5197 protein sequences generated from the whole genome sequence of IMT49658-1 (NCBI accession numbers CP135270-CP135274), a clinical ECC strain from our lab. Subsequently, protein-data filtering (contaminants, reverse hits and hits only identified by site) and statistical analysis was carried out with Perseus software version 1.6.14⁷⁴. Proteins were considered if at least 3 of 5 replicates per group showed LFQ intensity values. Normal distribution imputation added missing values near the detection limit using the default settings (width 0.3, down shift 1.8). Using student's *t*-test with a permutation-based FDR of 0.05 the differences of mean log₂ fold protein LFQ intensity between the two experimental groups (IMT49658-3—IMT49658-1) were calculated. Mean log₂ protein LFQ intensity differences with *p* < 0.05 and at least log₂ fold change >+1 for IMT49658-3 and <-1 for IMT49658-1 were considered as proteins with altered expression. In perseus, a volcano graph with mean log₂ fold protein LFQ intensity differences was plotted against -log₁₀ *p*-values (Fig. 2A).

DNA extraction

All DNA isolations were performed with standard protocols using the 'Isolation of genomic DNA from bacterial suspension cultures' protocol of Qiagen using the QIAamp DNA Mini Kit or the 'Master pure genomic DNA purification Kit' (Kit Epicentre) of Lucigen, sold by Biozym. The former was used with IMT49658-1 and IMT49658-3 for qPCR (GDA copy number detection) and WGS. Additionally, it was used with further inhibition zone and cell-lawn colonies from agar diffusion assays for qPCR and for Illumina Sequencing of 5 inhibition zone colonies and 4 heat treated samples of IMT49658-3. The standard protocol 'Genomic DNA purification from gram negative bacteria' from the Monarch HMW DNA Extraction Kit for tissue was used for five inhibition zone colonies of IMT49658-1Δ*catA2GDAshort* for nanopore sequencing with a subsequent DNA clean up and size selection step using High PrepTM PCR magnetic beads (MagBio Genomics Inc.) in a bead to sample ratio 0.4 to preselect long DNA fragments for further long read sequencing (Oxford Nanopore MinION). When GDA copy number was of interest, cells were directly cultured from cryotube into LB broth omitting an interim culturing on LB plates in order to avoid GDA copy number loss by additional cell growth. For the same reason DNA extraction started as soon as the culture had an OD_{600nm} of 0.5.

RNA extraction

RNA extraction was used for IMT49658-1 and IMT49658-3 for subsequent RT-qPCR gene expression measurements of β-lactamases using standard protocols of the Purification of total RNA from bacteria using RNeasy Mini Kit from Qiagen.

Whole-genome sequencing (WGS) and genome analysis

WGS of IMT 49658-1 and IMT 49658-3, inhibition zone colonies IMT 49658-1 CFU1, 6, 9, 10 and 11. WGS was performed for both IMT49658-1 and IMT49658-3, as well as for inhibition zone colonies

IMT49658-1 CFU1, 6, 9, 10 and 11. In brief, short-read sequencing was performed for all isolates on an Illumina NextSeq 550 platform using the NextSeq Reagent Kit v2.5 High Output (Illumina Inc., San Diego, CA, USA) and the Library Preparation Kit Nextera XT (Illumina), resulting in 150 bp paired-end reads and at an ~100× coverage. Additionally, samples were subjected to long-read sequencing using Oxford Nanopore MinION (Oxford, UK). MinION one-dimensional (1D) libraries were constructed using the SQK-RBK004 kit (Nanopore technologies, Oxford, UK) and loaded onto an R9.4 flow cell according to the manufacturer's instructions. Sequencing data was then collected for a total of 48 h. Amounts of 1 ng and 400 ng of extracted DNA were used as starting materials for sequencing by Illumina MiSeq and MinION technologies, respectively. Quality control of raw sequencing data (quality filtering, adaptor removal) was performed using an in-house pipeline.

WGS of IMT 49658-1 Δ*catA2GDAshort* CFU1_P1, CFU2_P1, CFU3_P2, CFU4_P2 and CFU5_P3. Isolates were subjected to long-read sequencing using Oxford Nanopore MinION (Oxford, UK). MinION one-dimensional (1D) libraries were constructed using the SQK-RBK114.24 kit (Nanopore technologies, Oxford, UK) and loaded onto an R10.4.1 flow cell according to the manufacturer's instructions. Sequencing data was then collected for a total of 48 h. Amounts of 200 ng of extracted DNA was used as starting materials for sequencing by MinION technologies. Further, we performed adaptor trimming on sequencing data with porechop v0.2.4 (<https://github.com/rrwick/Porechop>) and a removal of reads <1000 bp with Filtrlong v0.2.1 (<https://github.com/rrwick/Filtrlong>). Finally, quality check for the length of raw reads was assessed with LongQC⁷⁵ (<https://github.com/yfukasawa/LongQC>).

WGS of heat-treated isolates. The four isolates (IMT49658-3-25-45C-P9, IMT49658-3-26-45C-P9, IMT49658-3-26-45C-P23 and IMT49658-3-27-45C-P29) and IMT49658-1 Δ*catA2GDAshort* CFU1_P1 were subjected to WGS with the Illumina MiSeq platform (Illumina, Inc., San Diego, USA). The 300 bp paired-end sequencing in 40-fold multiplexes was performed on the Illumina MiSeq platform with the MiSeq[®] Reagent Kit v3 (600 cycle) (Illumina Inc., San Diego, CA, USA), and the Nextera XT DNA Library Preparation Kit (Illumina) according to the manufacturer's recommendations. The 300 bp paired-end reads were trimmed with Trim Galore (https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/) and de novo assembled into contigs using Unicycler v0.4.9 at default settings.

Postprocessing of WGS data and genome analysis. Multiple approaches were utilised to reconstruct the genomes of the selected strains. Initially, closed genomes of IMT49658-1 and IMT49658-3 were generated through de-novo hybrid-assembly using a combination of both short- and long-reads with Unicycler v0.4.7⁶. The Unicycler algorithm first utilises the short-reads to reconstruct contigs which are then extended through the additional long-read sequences. Reconstructed genomes were then annotated using Bakta v1.6.1⁷⁷ and RAST⁷⁸, followed by SNP analysis with Snippy v4.6.0. In addition, hybrid-assemblies were generated for IMT49658-1 and IMT49658-3 using the assembly workflow of the CLC Genomics Workbench. This method accurately represents repetitive or amplified regions because it first utilises the long-reads to create a genomic scaffold and then uses the short-reads to improve the per-base-accuracy. GDA was identified within the assembly of IMT49658-3 through dot plot comparison with IMT49658-1 and verified by investigating the raw reads within the CLC Genomics Workbench. Additionally, a custom BLAST database was constructed to further assess the amount of GDAs present within IMT49658-3. Finally, closed genomes were reconstructed for IMT49658-1 CFU 1, 6, 9, 10, 11 and IMT49658-1Δ*catA2GDAshort* CFU 1_P1 using the long-read assembler Flye v2.9.1-b1780⁷⁹, followed by additional quality-polishing using HyPo v1.0.3⁸⁰ in conjunction with the Illumina short-reads.

A ring comparison of both IMT49658-1 and IMT49658-3 was created through the CGView platform (<http://cgview.ca>). Annotated genomes were hereby uploaded to the platform in order to generate a comparative ring visualisation including coding sequences and GC content (Fig. 2B).

In addition, genomes of IMT49658-1, IMT49658-3, of heat cured strains and of 5 inhibition zone colonies were analysed using Geneious software version 11.1.5 (<https://www.geneious.com>). Comparison of single genes or bigger genetic fragments were done with Geneious algorithm using the ‘mapping to reference’ and ‘pairwise alignment’ option. Heat cured strains missing plasmid located genes were additionally assessed with mauve alignment algorithm implemented in Geneious. Furthermore, we used the PlasmidFinder 2.1 of the Center for Genomic Epidemiology (CGE) of the technical university of Denmark version 2.0.1 (<https://cge.food.dtu.dk/services/PlasmidFinder/>) in IMT49658-1 and IMT49658-3. Resistance genes in IMT49658-1 and IMT49658-3 were detected with ABRicate (<https://github.com/tseemann/abricate>, commit 955d402) using the NCBI, MEGARES and ResFinder Databases and with Resistance Gene Identifier (RGI) (<https://card.mcmaster.ca/analyze/rgi>) using the Comprehensive Antibiotic Resistance Database (CARD).

Gene expression analysis with RT-qPCR

RT-qPCR was performed with IMT49658-1 and IMT49658-3 for genes *AmpR/bla_{DHA-1}*, *bla_{DHA-1}*, *AmpR/bla_{ACT-16}*, *bla_{TEM}* and *bla_{CTX}*. Initially, we applied RNeasy Mini Kit (Qiagen) standard protocols to receive RNA, as indicated in the method-section ‘RNA-extraction’. Afterwards, we used RQ1 RNase free DNase (Promega) according to the manufacturer’s suggestion to erase remaining DNA. RNA concentration and purity was assessed with NanoDrop 1000 Spectrophotometer (Thermo Fisher Scientific) (A260/A280; ≥ 1.9 , A260/A230 ≥ 1.9). Then a control-qPCR for RNA purity with 25 ng/well of DNase digested RNA, using Power SYBR Green Master Mix (Thermo Fisher Scientific) was performed. In case no DNA contamination was detected (no fluorescence signals or a Ct bigger than 35), we generated complementary DNA (cDNA) according to the manufacturers instruction with 840 ng before approved RNA using RevertAID and Riboblock (reverse transcriptase and rnase inhibitor, Thermo Fisher Scientific). Finally, qPCR was conducted with 42 ng/well cDNA, performing technical triplicates per analysed gene, in 96 well plates (Eppendorf twin-tec® PCR Plate 96, unskirted, white). We used PCR cyler StepOnePlus™ and Power SYBR Green Master Mix.

For gene expression analysis we used the $2^{-\Delta\Delta Ct}$ -method. Here, normalisation was performed with the house keeping gene tryptophan synthetase β -chain (*trp*), resulting in ΔCt values. Final $2^{-\Delta\Delta Ct}$ -values were generated after subtracting ΔCt values of IMT49658-3 (sample) from ΔCt values of IMT49658-1 (control), receiving $\Delta\Delta Ct$ values and a relative fold change gene expression, using the formula $2^{-\Delta\Delta Ct}$. Finally, graphical presentation in GraphPad Prism was done showing Median and IQR per analysed gene.

Plasmid copy number detection

For the detection of plasmid copy number comparing IMT49658-1 and IMT49658-3 representing resistant subpopulation with GDA on the plasmid we calculate the ratio of plasmid DNA and chromosomal DNA using the formula $2^{-\Delta\Delta Ct}$. Here, ΔCt is the difference in threshold cycles between two plasmid genes using primerpairs *repA_1* & *repA_279* and the chromosomal genes *trpA*, *glnA* and *rpoB*. Relative fold change values of plasmid copy number in IMT49658-3 to IMT49658-1 was calculated from the subtraction of ΔCt values from resistant clones ‘sample’ to susceptible clones ‘control’ and the subsequent use of the $2^{-\Delta\Delta Ct}$ formula. For the detection of plasmid copy number per strain, IMT49658-1 and IMT49658-3 separately we used the formula $2^{-\Delta Ct}$, as previously described by Wang et al.⁸¹

Gene duplication-amplification (GDA) copy number inference using qPCR

GDA copy number was determined using qPCR from IMT49658-3, nine additional inhibition zone colonies and ten revertants of the reversal of

resistance and early and late occurring colonies from ScanLag experiments with 32 $\mu\text{g/ml}$ CAZ. In addition, GDA copy number was detected from IMT49658-1 $\Delta catA2\Delta recA$ after overnight growth in 16 $\mu\text{g/ml}$ CAZ. Extraction of genomic DNA (gDNA) was performed as above for WGS and qPCR. We used 6,7 ng gDNA/well using the same 96 well plates, PCR cyler and Master Mix as described above for the RT-qPCR experiments. Ct values of *AmpR/bla_{DHA-1}* and *bla_{DHA-1}* represented the amplified region and the house-keeping gene *trp* the control sequence apart from the GDA. For GDA copy number calculation we used the $2^{-\Delta\Delta Ct}$ -method. First, normalisation was conducted using *trp*, achieving ΔCt values and subsequently relative fold change values of GDA copy number was calculated from the subtraction of ΔCt values from resistant clones ‘sample’ from susceptible clones ‘control’ and the use of the $2^{-\Delta Ct}$ formula. Here IMT49658-1 or cell lawn colony outside the inhibition zone from the 9 mentioned inhibition zone colonies were used as control. To verify that the 17 kbp region was amplified, we used five different colonies from the inhibition zone of IMT49658-1 on CAZ and using primer pairs for the genes for dihydropteroate synthase, IS91 family transposase and the *sapA*, *pspA* and *qnrB* genes.

Gene duplication-amplification (GDA) copy number inference using Illumina raw reads

GDA copy number was inferred with Illumina raw reads by calculating the following quotient: average coverage amplified product / average coverage non-amplified product (Supplementary File 1, Table 4). The amplified product of IMT49658 consists of ~17 kbp (51.5% GC content) for 4 of 5 inhibition zone colonies and ~28 kbp (54% GC content) for the remaining 1 inhibition zone colony. The non-amplified plasmid-product has 4 kbp (41.6% GC content). The average coverage of both products used in the aforementioned quotient were extracted from Geneious after mapping the Illumina raw reads to the respective reference sequence.

Analysis of individual nanopore raw reads

In order to assess the heterogeneity of GDA copy numbers per inhibition zone colony (CFU), analysis of individual long reads spanning the amplified region was performed for five CFUs (IMT49658-1 $\Delta catA2$ GDashort CFU 1_P1, CFU2_P1, CFU3_P2, CFU4_P2, CFU5_P3). First, long ONT reads were mapped to the amplified region using minimap⁸² (v2.17-r941), in nanopore mode (‘-ax map-ont’), discarding secondary alignments (‘-sec-ondary=no’) and only reporting hits in the resulting sam file (‘-sam-hit-only’). Reads containing the amplified region (e.g. mapped reads) were then extracted from the sam files using the ‘SamToFastq’ function of picard (v2.18.29-SNAPSHOT), <http://broadinstitute.github.io/picard>. Seqtk (v1.3-r106), <https://github.com/lh3/seqtk>, was then utilised to preprocess each read individually before re-mapping the previously reconstructed ‘upstream’ and ‘downstream’ regions of the GDAs back to the filtered read set using minimap. Specifically, ~20 kb surrounding the GDAs were extracted and defined as ‘upstream’ and ‘downstream’ regions. A custom Python script was then utilised to assess the presence, absence and GDA counts per mapped read. Finally, the average PHRED score was assessed per read. Results were merged and exported into tabular format using R (v4.4.0) for further assessment in Microsoft Excel. The final graph (Fig. 3C) was created for IMT49658-1 CFU 1_P1 with Inkscape vector graphics editor (Inkscape Project. (2020). *Inkscape*. Retrieved from <https://inkscape.org>) and Microsoft PowerPoint. All reads displayed had a PHRED score of at least 16 (3% error rate). After additional annotation through the Rast⁷⁸ pipeline, GDA copy numbers in raw reads were once more manually verified within Geneious. Estimation of the lengths from both sides of spanning reads was conducted in Geneious counting 0.8 mm for 7 kbp.

Wanner mutagenesis in *Enterobacter cloacae* complex (ECC)

Gene deletion mutagenesis of *catA2*, *bla_{DHA-1}*, *recA* and the deletion of sequence for reduction of the plasmid p49658 GDA fragment from ~17 kbp to ~7 kbp was performed using the λ Red recombinase gene deletion/replacement protocol essentially as previously described⁸³, with minor modifications. Briefly, a derivative of plasmid pKD4 was constructed in

which the kanamycin-resistance cassette was replaced with a bleomycin/phleomycin-resistance cassette amplified by PCR using the plasmid pMSG360zeo⁸⁴ (Addgene, cat. #27154) as a template, and cloned as an *Xba*I fragment into the *Xba*I sites of pKD4 to generate plasmid pKD4ble. Putative clones were sequenced to verify the sequence integrity and orientation of the FLP recognition target (FRT) and P1 and P2 priming sites flanking the bleomycin/phleomycin-resistance cassette. Plasmid pKD4ble was subsequently used as a template for generation of the mutagenic PCR products. For deletion of sequence to reduce the size of the GDA, plasmid p2795⁸⁵ containing a kanamycin/neomycin-resistance cassette was used as a template for generation of mutagenic PCR products essentially as described above. After purification, the mutagenic PCR products were introduced by electroporation into electrocompetent *Enterobacter cloacae* (ECC) harbouring plasmid pSIM18⁸⁶, encoding hygromycin-resistance and a heat-inducible, λ Red recombinase, as previously described⁸⁷. Mutant selection was performed by plating of the bacteria to plates containing 15 μ g/ml phleomycin. For sequence deletion of the GDA, selection was performed on plates containing 50 μ g/ml neomycin. After verification of the gene/sequence deletions by PCR and sequencing, electrocompetent cells were prepared from the putative mutants and the antibiotic-resistance cassettes were eliminated by introduction of plasmid pCP20⁸⁸ encoding Flp recombinase and subsequent screening for loss of the antibiotic resistance and additional PCR verification. Clones which had lost the antibiotic resistance were subsequently cured of plasmid pCP20 by growth at 37 °C, and screening for loss of plasmid-derived chloramphenicol resistance at 30 °C, as previously described⁸⁸. To facilitate subsequent mutagenesis, deletion of the plasmid p49658-encoded, chloramphenicol-resistance *catA2* gene was performed first, and all further gene and sequence deletions were performed in the Δ *catA2* background in order to permit chloramphenicol selection and screening for plasmid pCP20. The primers used for all strain and plasmid constructions are listed in Supplementary Table S1.

Statistics

Statistics was done using Graphpad Prism. Significance of the appearance times from ECC source population and its heteroresistant phenotypes in ScanLag was tested with Mann-Whitney-U Test (Fig. 3D, Supplementary Fig. S6). We did a spearman correlation to investigate the relation between GDA and inhibition zone of agar-disk diffusion assays (Fig. 3B, inset). Unpaired student *t*-test was performed on the average GDA-copy number of late and early occurring colonies in ScanLag (Fig. 3E). For deeper statistical analyses of colony growth in ScanLag (Fig. 3F, Supplementary Table S7) we used statistical model comparison based on AIC⁸⁹, assuming that a Δ AIC > 2 suggest substantially better support of a given model. We fitted negative binomial distributed error structured generalised linear models with a log link function (package MASS function glm.nb). Model comparison included for all models the colony size (in pixels) as response variable, and as explanatory variables combinations of the factors time, a quadratic function of time, GDA, treatment (i.e. 32 μ g/ml CAZ or control 0 μ g/ml CAZ), and lag time. Interactions among these explanatory factors were explored with a focus on interactions among growth rates and GDA (time and amplification) (see Supplementary File 2, Table 7). To reduce model complexity (interactions) and for ease of interpretation, we set the time of all colonies when they passed the detection threshold (>10 pixel) to time = 0, even though lag times differed among colonies. The actual differences in when they reached the threshold is conserved in the factor lag time.

Data availability

Raw sequencing data, chromosomes and plasmids are deposited at NCBI: NCBI bioproject number: PRJNA102068. IMT 49658-1 can be found under the biosample number: SAMN37527804, Genbank accession numbers CP135270-CP135274. IMT 49658-3 can be found under the biosample number SAMN44249573, (Genbank accession numbers CP173198-CP173202). IMT49658-1 Δ *catA2*GDAshort can be found under the biosample number SAMN44250108, and the raw reads in the sequence read

archive SRX26352414. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE⁹⁰ partner repository with the dataset identifier PXD056728.

Received: 21 July 2024; Accepted: 18 November 2024;

Published online: 22 February 2025

References

- World Health Organization. *Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022*. Licence: CC BY-NC-SA 3.0 IGO (World Health Organization, 2022).
- Murray, C. J. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. *Lancet* **399**, 629–655 (2022).
- O'Neill, J. *Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations: The Review on Antimicrobial Resistance* (Wellcome Trust, London, England, 2014).
- Jonas, O. B., Irwin, A., Berthe, F. C. J., Le Gall, F. G. & Marquez, P. V. Drug-resistant infections: a threat to our economic future. *World Bank Rep.* **2**, 1–3 (2017).
- Llor, C. & Bjerrum, L. Antimicrobial resistance: risk associated with antibiotic overuse and initiatives to reduce the problem. *Ther. Adv. Drug Saf.* **5**, 229 (2014).
- Ventola, C. L. The Antibiotic resistance crisis: part 1: causes and threats. *Pharm. Ther.* **40**, 277 (2015).
- World Health Organization. *2021 Antibacterial Agents in Clinical and Preclinical Development: an Overview and Analysis* (World Health Organization, 2022).
- Band, V. I. & Weiss, D. S. Heteroresistance: a cause of unexplained antibiotic treatment failure? *PLoS Pathog.* **15**, e1007726 (2019).
- Munita, J. M. & Arias, C. A. Mechanisms of antibiotic resistance. *Virulence Mech. Bact. Pathog.* 481–511. <https://doi.org/10.1128/9781555819286.CH17> (2016).
- Corona, F. & Martinez, J. L. Phenotypic resistance to antibiotics. *Antibiotics* **2**, 237–255 (2013).
- Balaban, N. Q. et al. Definitions and guidelines for research on antibiotic persistence. *Nat. Rev. Microbiol.* **17**, 441–448 (2019).
- Alexander, H. E. & Leidy, G. Mode of action of streptomycin on type b hemophilus influenzae: II. Nature of resistant variants. *J. Exp. Med.* **85**, 607 (1947).
- El-Halfawy, O. M. & Valvano, M. A. Antimicrobial heteroresistance: an emerging field in need of clarity. *Clin. Microbiol. Rev.* **28**, 191–207 (2015).
- Andersson, D. I., Nicoloff, H. & Hjort, K. Mechanisms and clinical relevance of bacterial heteroresistance. *Nat. Rev. Microbiol.* **17**, 479–496 (2019).
- Roch, M., Sierra, R. & Andrey, D. O. Antibiotic heteroresistance in ESKAPE pathogens, from bench to bedside. *Clin. Microbiol. Infect.* **29**, 320–325 (2023).
- Arvaniti, M. & Skandamis, P. N. Defining bacterial heterogeneity and dormancy with the parallel use of single-cell and population level approaches. *Curr. Opin. Food Sci.* **44**, 100808 (2022).
- Brauner, A., Fridman, O., Gefen, O. & Balaban, N. Q. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. *Nat. Rev. Microbiol.* **14**, 320–330 (2016).
- Cheong, W. S. J., Harris, P., Oman, K. & Norton, R. Challenges in the microbiological diagnosis and management of hVISA infections. *Pathology* **43**, 357–361 (2011).
- Band, V. I. et al. Colistin heteroresistance is largely undetected among carbapenem-resistant enterobacterales in the United States. *MBio* **12**, 1–7 (2021).
- da Silva, A. E. B., Martins, A. F., Nodari, C. S., Magagnin, C. M. & Barth, A. L. Carbapenem-heteroresistance among isolates of the *Enterobacter cloacae* complex: is it a real concern? *Eur. J. Clin. Microbiol. Infect. Dis.* **37**, 185–186 (2018).

21. Liu, H. et al. Detection and characterization of tigecycline heteroresistance in *E. cloacae*: clinical and microbiological findings. *Emerg. Microbes Infect.* **8**, 564–574 (2019).
22. Kang, K. N. et al. Colistin heteroresistance in *Enterobacter cloacae* is regulated by PhoPQ-dependent 4-amino-4-deoxy-L-arabinose addition to lipid A. *Mol. Microbiol.* **111**, 1604–1616 (2019).
23. Liu, S. et al. Characterization of resistance mechanisms of *Enterobacter cloacae* complex co-resistant to carbapenem and colistin. *BMC Microbiol.* **21**, 208 (2021).
24. Huang, L., Feng, Y. & Zong, Z. Heterogeneous resistance to colistin in *Enterobacter cloacae* complex due to a new small transmembrane protein. *J. Antimicrob. Chemother.* **74**, 2551–2558 (2019).
25. Nicoloff, H., Hjort, K., Levin, B. R. & Andersson, D. I. The high prevalence of antibiotic heteroresistance in pathogenic bacteria is mainly caused by gene amplification. *Nat. Microbiol.* **4**, 504–514 (2019).
26. Riehle, M. M., Bennett, A. F. & Long, A. D. Genetic architecture of thermal adaptation in *Escherichia coli*. *Proc. Natl. Acad. Sci. USA* **98**, 525–530 (2001).
27. Brown, C. J., Todd, K. M. & Rosenzweig, R. F. Multiple duplications of yeast hexose transport genes in response to selection in a glucose-limited environment. *Mol. Biol. Evol.* **15**, 931–942 (1998).
28. Kondrashov, F. A. Gene duplication as a mechanism of genomic adaptation to a changing environment. *Proc. R. Soc. B Biol. Sci.* **279**, 5048–5057 (2012).
29. Harmer, C. J., Lebreton, F., Stam, J., McGann, P. T. & Hall, R. M. Mechanisms of IS 26-mediated amplification of the *aphA1* gene leading to tobramycin resistance in an *Acinetobacter baumannii* isolate. *Microbiol. Spectr.* **10**, e0228722 (2022).
30. Silva, K. P. T., Sundar, G. & Khare, A. Efflux pump gene amplifications bypass necessity of multiple target mutations for resistance against dual-targeting antibiotic. *Nat. Commun.* **14**, 1–14 (2023).
31. Hjort, K., Nicoloff, H. & Andersson, D. I. Unstable tandem gene amplification generates heteroresistance (variation in resistance within a population) to colistin in *Salmonella enterica*. *Mol. Microbiol.* **102**, 274–289 (2016).
32. Tomanek, I. et al. Gene amplification as a form of population-level gene expression regulation. *Nat. Ecol. Evol.* **4**, 612–625 (2020).
33. Andersson, D. I. & Hughes, D. Gene amplification and adaptive evolution in bacteria. *Annu. Rev. Genet.* **43**, 167–195 (2009).
34. Baumgart, L. A. et al. Persistence and plasticity in bacterial gene regulation. *Nat. Methods* **18**, 1499–1505 (2021).
35. Pereira, C., Larsson, J., Hjort, K., Elf, J. & Andersson, D. I. The highly dynamic nature of bacterial heteroresistance impairs its clinical detection. *Commun. Biol.* **4**, 521 (2021).
36. Band, V. I. et al. Antibiotic combinations that exploit heteroresistance to multiple drugs effectively control infection. *Nat. Microbiol.* **4**, 1627–1635 (2019).
37. Gollan, B., Grabe, G., Michaux, C. & Helaine, S. Bacterial persists and infection: past, present, and progressing. *Annu. Rev. Microbiol.* **73**, 359–385 (2019).
38. Melnyk, A. H., Wong, A. & Kassen, R. The fitness costs of antibiotic resistance mutations. *Evol. Appl.* **8**, 273–283 (2015).
39. Bonnefoy, A. et al. In vitro activity of AVE1330A, an innovative broad-spectrum non-beta-lactam beta-lactamase inhibitor. *J. Antimicrob. Chemother.* **54**, 410–417 (2004).
40. Guérin, F., Isnard, C., Cattoir, V. & Giard, J. C. Complex regulation pathways of AmpC-mediated β -lactam resistance in *Enterobacter cloacae* complex. *Antimicrob. Agents Chemother.* **59**, 7753–7761 (2015).
41. Shaheen, B. W. et al. Molecular characterization of resistance to extended-spectrum cephalosporins in clinical *Escherichia coli* isolates from companion animals in the United States. *Antimicrob. Agents Chemother.* **55**, 5666–5675 (2011).
42. Schaufler, K., Wieler, L. H., Semmler, T., Ewers, C. & Guenther, S. ESBL-plasmids carrying toxin-antitoxin systems can be “cured” of wild-type *Escherichia coli* using a heat technique. *Gut Pathog.* **5**, 34 (2013).
43. Reams, A. B. & Roth, J. R. Mechanisms of gene duplication and amplification. *Cold Spring Harb. Perspect. Biol.* **7**, a016592 (2015).
44. Reams, A. B., Kofoid, E., Kugelberg, E. & Roth, J. R. Multiple pathways of duplication formation with and without recombination (RecA) in *Salmonella enterica*. *Genetics* **192**, 397–415 (2012).
45. Jain, M. et al. Nanopore sequencing and assembly of a human genome with ultra-long reads. *Nat. Biotechnol.* **36**, 338–345 (2018).
46. Girgis, H. S. et al. Single-molecule nanopore sequencing reveals extreme target copy number heterogeneity in arylomycin-resistant mutants. *Proc. Natl. Acad. Sci. USA* **118**, e2021958118 (2020).
47. Levin-Reisman, I., Fridman, O. & Balaban, N. Q. Scanlag: high-throughput quantification of colony growth and lag time. *J. Vis. Exp.* 1–15. <https://doi.org/10.3791/51456> (2014).
48. Woodford, N. & Ellington, M. J. The emergence of antibiotic resistance by mutation. *Clin. Microbiol. Infect.* **13**, 5–18 (2007).
49. Dawan, J. & Ahn, J. Bacterial stress responses as potential targets in overcoming antibiotic resistance. *Microorganisms* **10**, 1385 (2022).
50. Nicoloff, H., Hjort, K., Andersson, D. I. & Wang, H. Three concurrent mechanisms generate gene copy number variation and transient antibiotic heteroresistance. <https://doi.org/10.1038/s41467-024-48233-0> (2024).
51. Sandegren, L. & Andersson, D. I. Bacterial gene amplification: implications for the evolution of antibiotic resistance. *Nat. Rev. Microbiol.* **2009** **78**, 578–588 (2009).
52. Davis, K. M. & Isberg, R. R. Defining heterogeneity within bacterial populations via single cell approaches. *BioEssays* **38**, 782–790 (2016).
53. van der Woude, M. W. Phase variation: how to create and coordinate population diversity. *Curr. Opin. Microbiol.* **14**, 205–211 (2011).
54. Ronin, I., Katsowich, N., Rosenshine, I. & Balaban, N. Q. A long-term epigenetic memory switch controls bacterial virulence bimodality. *Elife* **6**, e19599 (2017).
55. Nielsen, A. T. et al. A bistable switch and anatomical site control *Vibrio cholerae* virulence gene expression in the intestine. *PLoS Pathog.* **6**, e1001102 (2010).
56. Atack, J. M. et al. A biphasic epigenetic switch controls immunoevasion, virulence and niche adaptation in non-typeable *Haemophilus influenzae*. *Nat. Commun.* **61**, 1–12 (2015).
57. Anderson, P. & Roth, J. Spontaneous tandem genetic duplications in *Salmonella typhimurium* arise by unequal recombination between rRNA (rm) cistrons. *Proc. Natl. Acad. Sci. USA* **78**, 3113–3117 (1981).
58. Flores, M. et al. Prediction, identification, and artificial selection of DNA rearrangements in *Rhizobium*: toward a natural genomic design. *Proc. Natl. Acad. Sci. USA* **97**, 9138–9143 (2000).
59. Saathoff, M. et al. Gene amplifications cause high-level resistance against albicidin in gram-negative bacteria. *PLoS Biol.* **21**, e3002186 (2023).
60. Reams, A. B. & Neidle, E. L. Gene amplification involves site-specific short homology-independent illegitimate recombination in *Acinetobacter* sp. strain ADP1. *J. Mol. Biol.* **338**, 643–656 (2004).
61. Nilsson, A. I. et al. Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. *Proc. Natl. Acad. Sci. USA* **103**, 6976–6981 (2006).
62. Ikeda, H., Shiraishi, K. & Ogata, Y. Illegitimate recombination mediated by double-strand break and end-joining in *Escherichia coli*. *Adv. Biophys.* **38**, 3–20 (2004).
63. Gore, J. M., Ran, F. A. & Ornston, L. N. Deletion mutations caused by DNA strand slippage in *Acinetobacter baylyi*. *Appl. Environ. Microbiol.* **72**, 5239–5245 (2006).
64. Lovett, S. T., Drapkin, P. T., Sutura, V. A. & Gluckman-Peskind, T. J. A sister-strand exchange mechanism for recA-independent deletion of repeated DNA sequences in *Escherichia coli*. *Genetics* **135**, 631–642 (1993).

65. Adler, M., Anjum, M., Berg, O. G., Andersson, D. I. & Sandegren, L. High fitness costs and instability of gene duplications reduce rates of evolution of new genes by duplication-divergence mechanisms. *Mol. Biol. Evol.* **31**, 1526–1535 (2014).
66. Pettersson, M. E., Sun, S., Andersson, D. I. & Berg, O. G. Evolution of new gene functions: simulation and analysis of the amplification model. *Genetica* **135**, 309–324 (2009).
67. Jolley, K. A. et al. Ribosomal multilocus sequence typing: universal characterization of bacteria from domain to strain. *Microbiology* **158**, 1005–1015 (2012).
68. CLSI. *Performance Standards for Antimicrobial Disk and Dilution Susceptibility Tests for Bacteria Isolated From Animals* 5th ed. CLSI supplement VET01S. (Clinical and Laboratory Standard Institute, 2020).
69. Miller, W. G., Leveau, J. H. J. & Lindow, S. E. Improved gfp and inaZ broad-host-range promoter-probe vectors. *Mol. Plant. Microbe Interact.* **13**, 1243–1250 (2000).
70. Levin-Reisman, I. et al. Automated imaging with ScanLag reveals previously undetectable bacterial growth phenotypes. *Nat. Methods* **7**, 737–739 (2010).
71. Wareth, G. et al. Comprehensive Identification of immunodominant proteins of *Brucella abortus* and *Brucella melitensis* using antibodies in the sera from naturally infected hosts. *Int. J. Mol. Sci.* **17**, 659 (2016).
72. Rappsilber, J., Ishihama, Y. & Mann, M. Stop and go extraction tips for matrix-assisted laser desorption/ionization, nanoelectrospray, and LC/MS sample pretreatment in proteomics. *Anal. Chem.* **75**, 663–670 (2003).
73. Tyanova, S., Temu, T. & Cox, J. The MaxQuant computational platform for mass spectrometry-based shotgun proteomics. *Nat. Protoc.* **11**, 2301–2319 (2016).
74. Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. *Nat. Methods* **13**, 731–740 (2016).
75. Fukasawa, Y., Ermini, L., Wang, H., Carty, K. & Cheung, M. S. LongQC: a quality control tool for third generation sequencing long read data. *G3* **10**, 1193–1196 (2020).
76. Wick, R. R., Judd, L. M., Gorrie, C. L. & Holt, K. E. Unicycler: resolving bacterial genome assemblies from short and long sequencing reads. *PLoS Comput. Biol.* **13**, 1–22 (2017).
77. Schwengers, O. et al. Bakta: rapid and standardized annotation of bacterial genomes via alignment-free sequence identification. *Microb. Genom.* **7**, 000685 (2021).
78. Aziz, R. K. et al. The RAST Server: rapid annotations using subsystems technology. *BMC Genom.* **9**, 1–15 (2008).
79. Kolmogorov, M., Yuan, J., Lin, Y. & Pevzner, P. A. Assembly of long, error-prone reads using repeat graphs. *Nat. Biotechnol.* **37**, 540–546 (2019).
80. Kundu, R., Casey, J. & Sung, W.-K. HyPo: super fast & accurate polisher for long read genome assemblies. *bioRxiv* 2019.12.19.882506. <https://doi.org/10.1101/2019.12.19.882506> (2019).
81. Wang, H. et al. Increased plasmid copy number is essential for *Yersinia T3SS* function and virulence. *Science* **353**, 492–495 (2016).
82. Li, H. Minimap2: pairwise alignment for nucleotide sequences. *Bioinformatics* **34**, 3094–3100 (2018).
83. Datsenko, K. A. & Wanner, B. L. One-step inactivation of chromosomal genes in *Escherichia coli* K-12 using PCR products. *Proc. Natl. Acad. Sci. USA* **97**, 6640–6645 (2000).
84. Barkan, D., Rao, V., Sukenick, G. D. & Glickman, M. S. Redundant function of *cmaA2* and *mmaA2* in *Mycobacterium tuberculosis* cis cyclopropanation of oxygenated mycolates. *J. Bacteriol.* **192**, 3661–3668 (2010).
85. Husseiny, M. I. & Hensel, M. Rapid method for the construction of *Salmonella enterica* Serovar Typhimurium vaccine carrier strains. *Infect. Immun.* **73**, 1598–1605 (2005).
86. Chan, W. et al. A recombineering based approach for high-throughput conditional knockout targeting vector construction. *Nucleic Acids Res.* **35**, e64 (2007).
87. Sharan, S. K., Thomason, L. C., Kuznetsov, S. G. & Court, D. L. Recombineering: a homologous recombination-based method of genetic engineering. *Nat. Protoc.* **4**, 206–223 (2009).
88. Cherepanov, P. P. & Wackernagel, W. Gene disruption in *Escherichia coli*: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. *Gene* **158**, 9–14 (1995).
89. Anderson, D. & Burnham, K. *Model Selection and Multimodel Inference*. <https://doi.org/10.1007/b97636> (Springer New York, 2004).
90. Perez-Riverol, Y. et al. The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences. *Nucleic Acids Res.* **50**, D543–D552 (2022).

Acknowledgements

This work was supported by the DFG priority programme SPP2225 (FU 1027/4-1 to M.F.), and the Collaborative Research Center CRC1449, Project ID 431232613; project B5 (to M.F. and F.G.). J.K. is financed by a scholarship from the H. Wilhelm Schaumann Foundation. M.F. received support by the Freie Universität Berlin within the Excellence Initiative of the German Research Foundation. For mass spectrometry, we would like to acknowledge the assistance of the Core Facility BioSupraMol supported by the Deutsche Forschungsgemeinschaft (DFG). In addition, we thank the Remus-Emsermann research group of the Institute of Biology, Freie Universität Berlin, for kindly providing the plasmid pMRE135 containing the mScarlet red fluorescence protein sequence.

Author contributions

Conceptualisation and study design: Johannes Kupke, Marcus Fulde, Karsten Tedin, Ulrich K. Steiner, Antina Lübke-Becker, Fereshteh Ghazisaeedi, Frank Schreiber, Niclas Nordholt. Performance of experiments: Johannes Kupke, Yuwen Fang, Julian Brombach, Karsten Tedin, Fereshteh Ghazisaeedi, Benno Kuroпка. Whole Genome Sequencing and subsequent evaluation: Johannes Kupke, Dennis Hanke, Torsten Semmler, Silver A. Wolf, Lakshmi Priya Thrukonda. Data creation with ScanLag experiments and subsequent evaluation: Johannes Kupke, Frank Schreiber, Dennis Hanke, Niclas Nordholt. Statistical modelling: Ulrich K. Steiner. Writing of manuscript: Johannes Kupke, Marcus Fulde, Ulrich K. Steiner, Frank Schreiber. Funding acquisition: Marcus Fulde.

Funding

Open Access funding enabled and organized by Projekt DEAL.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s44259-025-00082-7>.

Correspondence and requests for materials should be addressed to Marcus Fulde.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2025